Search results for " FIBROSIS"

showing 10 items of 490 documents

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct

Reply

2017

NASH FIBROSIS STIFFNESS0301 basic medicineSettore MED/12 - Gastroenterologia03 medical and health sciences030104 developmental biology0302 clinical medicineHepatologybusiness.industryMedicine030211 gastroenterology & hepatologybusinessHepatology
researchProduct

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

2021

Background & Aims Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay. Methods PRO-C3 was measured in 269 healthy volunteers…

NASH-CRN NASH Clinical Research NetworkBiopsyDiseaseAST aspartate aminotransferaseRC799-869Ethnic groupsGastroenterologyNIMBLE Non-Invasive Biomarkers of Metabolic Liver Disease (consortium)FibrosisImmunology and AllergyBody mass indexmedicine.diagnostic_testFatty liverNAS NAFLD Activity ScoreGastroenterologyDiseases of the digestive system. GastroenterologyHospitalsNPV negative predictive valueLiver biopsyBiomarker (medicine)Research Articlemedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseADAM A Disintegrin and MetalloproteasesNASH non-alcoholic steatohepatitisReference rangeReference valuesAUROC area under the receiver operating characteristics curveInternal medicineALT alanine aminotransferaseBiopsyInternal MedicinemedicineHumansFIB-4 fibrosis-4Healthy volunteersHepatologyALP alkaline phosphatasebusiness.industryCLSI Clinical and Laboratory Standards InstituteT2DM type 2 diabetes mellitusELF™ test Enhanced Liver Fibrosis testmedicine.diseaseLITMUS Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium)Collagen type IIIFibrosisPPV positive predictive valueReference standardsbusinessBody mass indexBiomarkersNon-alcoholic fatty liver disease
researchProduct

Staphylococcal Biofilms:Challenges in the Discovery of Novel Antiinfective Agents

2011

Staphylococci can induce a wide spectrum of infectious diseases that are associated with remarkable morbidity and mortality [1]. In fact, community and hospital-acquired methicillin resistant Staphylococcus aureus (MRSA) is a major health problem that has created a pressing need for novel therapeutic options [2]. Importantly, pathogenic staphylococci have not only an amazing ability to acquire resistance to antibiotics, but also to form biofilms, bacterial communities that grow on surfaces and are surrounded by a self-produced polymer matrix. This latter characteristic is likely the most important virulence factor of staphylococci in the development of the chronic form of infectious disease…

Native Valve Endocarditismedicine.drug_classOsteomyelitisAntibioticsBiofilmBiologymedicine.diseasemedicine.disease_causeApplied Microbiology and BiotechnologyBiochemistryMicrobiologyMethicillin-resistant Staphylococcus aureusCystic fibrosisMicrobiologyOtitismedicineSeptic arthritismedicine.symptomBiotechnologyJournal of Microbial & Biochemical Technology
researchProduct

Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.

2009

Background Nephrogenic systemic fibrosis (NSF) affects some patients on dialysis after gadolinium contrast agent–enhanced magnetic resonance imaging. It is characterized by progressive skin fibrosis of the extremities, sometimes including the trunk and internal organs. Methods The clinical course of 10 patients with biopsy-proven NSF was analyzed retrospectively with regard to gadolinium exposition, disease onset, and progression of NSF with special emphasis on physical mobility and impact of different therapeutic approaches. Results Despite physiotherapy and different additional therapeutic approaches (eg, immunosuppression, ultraviolet A-1 phototherapy, or extracorporal photopheresis) all…

Nephrogenic Fibrosing DermopathyAdultmedicine.medical_specialtymedicine.medical_treatmentBiopsyGadoliniumDermatologyHydronephrosisNephrectomyEnd stage renal diseaseNephrogenic Fibrosing DermopathyPhotopheresisFibrosisRenal DialysismedicineHumansKidney transplantationDialysisbusiness.industrymedicine.diseaseMagnetic Resonance ImagingSurgeryNephrogenic systemic fibrosisDisease ProgressionFemalebusinessKidney diseaseJournal of the American Academy of Dermatology
researchProduct

Areca nut and its role in oral submucous fibrosis

2014

Areca nut, commonly called as betel nut or supari, is a fruit of areca catechu palm tree, which is native of South Asia and Pacific Islands. The seed or endosperm is consumed fresh, boiled or after sun drying or curing. Chewing areca nut is thought to have central nervous system stimulating effect and along with this it is known to have salivary stimulating and digestive properties. According to the traditional Ayurvedic medicine, chewing areca nut and betel leaf is a good remedy against halitosis. It is also used for its deworming property. Along with these beneficial effects of areca nut one of its most harmful effects on the human body in general and oral cavity in particular is the deve…

NutAyurvedic medicineOdontologíaReviewCatechuOral cavitymedicineGeneral DentistryArecaOral Medicine and PathologyTraditional medicinebiologybusiness.industrydigestive oral and skin physiologyBetel leaffood and beverages:CIENCIAS MÉDICAS [UNESCO]Betelbiology.organism_classificationmedicine.diseaseCiencias de la saludstomatognathic diseasesOral submucous fibrosisUNESCO::CIENCIAS MÉDICASbusinessJournal of Clinical and Experimental Dentistry
researchProduct

Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer

2013

Use of anti-epidermal growth factor receptor (anti-EGFR) agents has yielded significant advances in the treatment of patients with metastatic colorectal cancer. In fact these drugs, which include the monoclonal antibodies cetuximab and panitumumab, can be delivered both as a single agent and in combination with chemotherapy, achieving better survival and quality of life and in some cases also resectability of metastases. However, these agents can result in the development of toxicities that are usually different from those observed with chemotherapy alone. For the management of these adverse effects, proper knowledge is mandatory. Skin toxicity is the most frequent adverse effect. Other tox…

OncologyColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPulmonary FibrosisCetuximabPharmacologyPrurituMagnesiumEpidermal growth factor receptorParonychiaCancerSkinbiologyCetuximabPanitumumabGastroenterologyfood and beveragesCutaneouOncologyToxicityMetastaticmedicine.drugDiarrheamedicine.medical_specialtyGastrointestinalAnti-epidermal growth factor receptorColonReactionInternal medicineRashmedicinePanitumumabToxicity; Epidermal growth factor receptor; Anti-epidermal growth factor receptor; Cetuximab; Panitumumab; Antibody; Metastatic; Colon; Rectum; Cancer; Treatment; Skin; Rash; Cutaneous; Pruritus; Xerosis; Paronychia; Hypomagnesemia; Magnesium; Gastrointestinal; Diarrhea; Infusion; Reaction; Pulmonary FibrosisInfusionAdverse effectAntibodyXerosisChemotherapyHepatologyToxicitybusiness.industryEpidermal growth factor receptorPruritusRectumCancermedicine.diseaseXerosiTreatmentCutaneousbiology.proteinHypomagnesemiabusiness
researchProduct

Ozone therapy in idiopathic carpal tunnel syndrome. Biochemical, neurophysiological and clinical aspects

2018

Purpose.
 Idiopathic Carpal Tunnel Syndrome (CTS) is the most common entrapment neuropathy; however few and only retrospective studies have been found in search engines about Ozone Therapy. 
 The aim of this paper was to evaluate clinical and neurophysiological outcome following Ozone Therapy in CTS.
 We focused the attention on the evidences concerning the role of Subsynovial Connective Tissue (SSCT) in the pathogenesis of CTS and the ozone pre-conditioning effects linked to pain and inflammatory pathways and to fibrosis induced by Ischemia-Reperfusion Injury.
 
 Materials and methods.
 Thirty-five patients, aged between 21 and 80, were stratified clinically b…

Oxidative stress Fibrosisbusiness.industryOzone therapy Carpal tunnel syndrome Ischemia reperfusion injury Oxidative stress Fibrosis TimingRetrospective cohort study:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOzone therapyPathophysiologymedicine.anatomical_structureFibrosisAnesthesiaUNESCO::CIENCIAS MÉDICASEntrapment NeuropathyOzone therapyCarpal tunnel syndrome Ischemia reperfusion injuryMedicineCarpal tunnelTimingbusinessCarpal tunnel syndromeSensory nerve
researchProduct

Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2.

2013

Background: Prostaglandin E2 (PGE(2)), the main metabolite of cyclooxygenase (COX), is a well-known anti-fibrotic agent. Moreover, myofibroblasts expressing alpha-smooth muscle actin (alpha-SMA), fibroblast expansion and epithelial-mesenchymal transition (EMT) are critical to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Our aim was to investigate the expression of COX-2 and PGE(2) in human lung myofibroblasts and establish whether fibroblast-myofibroblast transition (FMT) and EMT are associated with COX-2 and PGE(2) down-regulation. Methods: Fibroblasts obtained from IPF patients (n = 6) and patients undergoing spontaneous pneumothorax (control, n = 6) and alveolar epithelial ce…

PathologyPulmonologyMetaboliteImmunofluorescencelcsh:MedicineBiochemistrychemistry.chemical_compoundIdiopathic pulmonary fibrosisMolecular Cell BiologyPulmonary fibrosisProstaglandin E2Myofibroblastslcsh:ScienceLungCells CulturedFisiologia cel·lularMultidisciplinarybiologyFibrosi pulmonarrespiratory systemExtracellular Matrixmedicine.anatomical_structureCytokinesMedicinelipids (amino acids peptides and proteins)Immunohistochemical AnalysisMyofibroblastResearch ArticleSignal Transductionmedicine.drugmedicine.medical_specialtyEpithelial-Mesenchymal TransitionImmunologyInterstitial Lung DiseasesDinoprostonePulmonary fibrosisTransforming Growth Factor beta1ImmunofluorescènciaGrowth FactorsCell Line TumormedicineHumansEpithelial–mesenchymal transitionFibroblastBiologyCell Proliferationlcsh:RProteinsEpithelial Cellsmedicine.diseaseActinsIdiopathic Pulmonary Fibrosisrespiratory tract diseasesGene Expression RegulationchemistryCyclooxygenase 2Immune SystemCase-Control StudiesImmunologic Techniquesbiology.proteinCancer researchClinical Immunologylcsh:QCyclooxygenaseBiomarkersPLoS ONE
researchProduct

SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.

2011

Fibrosis results from inflammatory tissue damage and impaired regeneration. In the context of bleomycin-induced pulmonary fibrosis, we demonstrated that the matricellular protein termed secreted protein acidic and rich in cysteine (SPARC) distinctly regulates inflammation and collagen deposition, depending on its cellular origin. Reciprocal Sparc(-/-) and wild-type (WT) bone marrow chimeras revealed that SPARC expression in host fibroblasts is required and sufficient to induce collagen fibrosis in a proper inflammatory environment. Accordingly, Sparc(-/-) >WT chimeras showed exacerbated inflammation and fibrosis due to the inability of Sparc(-/-) macrophages to down-regulate tumor necrosis …

Pathologymedicine.medical_specialtyAnimals; Bleomycin; Bone Marrow Cells; Chimera; Collagen; Down-Regulation; Fibroblasts; Leukocytes; Macrophages; Mice; Mice Inbred BALB C; Osteonectin; Pneumonia; Pulmonary Fibrosis; Transforming Growth Factor beta; Tumor Necrosis Factor-alphaPulmonary FibrosisDown-RegulationInflammationBone Marrow CellsBiologyPathology and Forensic MedicineMiceFibrosisTumor necrosis factor productionTransforming Growth Factor betaPulmonary fibrosismedicineLeukocytesAnimalsOsteonectinInbred BALB CChimeraTumor Necrosis Factor-alphaMacrophagesMatricellular proteinRegular ArticleSPARCTransforming growth factor betaPneumoniaFibroblastsBLEOMYCINmedicine.diseaseSPARC; BLEOMYCIN; LUNG DAMAGELUNG DAMAGECancer researchbiology.proteinTumor necrosis factor alphaCollagenmedicine.symptomOsteonectin
researchProduct